Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.
The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果